Occurrence of Type 1 Diabetes in a Patient Enrolled in an Immunotherapy Combination Phase 1 Clinical Trial: A Case Study

被引：1

作者：

Charles, Sheena ^{[1
]}

Poullard, Anna ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut A Phase 1 Program, Houston, TX 77030 USA

来源：

ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING | 2021年 / 8卷 / 06期

关键词：

Immune checkpoint inhibitors; immunotherapy; Type; 1; diabetes;

D O I：

10.4103/apjon.apjon-2122

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Advances in cancer immunotherapy treatments have shown promising results in patients with metastatic malignancy who have been refractory to prior treatments. Immune checkpoint inhibitors such as pembrolizumab in combination with other systemic agents may unleash immune-related adverse events (irAEs). Immunotherapy-induced Type 1 diabetes is rare; however, if left undiagnosed, it may cause life-threatening metabolic endocrinopathies. Advanced practice registered nurses are in a unique position to recognize and identify this irAE and in doing so can provide pathways for early diagnosis and treatments, thus leading to improved clinical and patient outcomes.

引用

页码：737 / 739

页数：3

共 50 条

[41] IMMUNOPATHOGENESIS AND IMMUNOTHERAPY OF TYPE-1 DIABETES
WILSON, K
EISENBARTH, GS
ANNUAL REVIEW OF MEDICINE, 1990, 41 : 497 - 508
[42] Immunotherapy of type 1 diabetes: new avenues
Mallone, Roberto
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2013, 17 (03): : 60 - 64
[43] Depression in type 1 diabetes and type 2 diabetes: Linking patient experience with clinical records
Stedman, M.
Eltom, S.
Solomon, E.
Rea, R.
McGoughlin, K.
Nouwen, A.
Grady, C.
Paisley, S. Brown A.
Heald, A. H.
DIABETIC MEDICINE, 2022, 39
[44] Depression in type 1 diabetes and type 2 diabetes: linking patient experience with clinical records
Waheed, U.
Heald, A. H.
Paisley, A.
Grady, K.
Solomon, E.
Stedman, M. P.
DIABETOLOGIA, 2022, 65 (SUPPL 1) : S357 - S357
[45] Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
Assfalg, Robin
Knoop, Jan
Hoffman, Kristi L.
Pfirrmann, Markus
Zapardiel-Gonzalo, Jose Maria
Hofelich, Anna
Eugster, Anne
Weigelt, Marc
Matzke, Claudia
Reinhardt, Julia
Fuchs, Yannick
Bunk, Melanie
Weiss, Andreas
Hippich, Markus
Halfter, Kathrin
Hauck, Stefanie M.
Hasford, Jorg
Petrosino, Joseph F.
Achenbach, Peter
Bonifacio, Ezio
Ziegler, Anette-Gabriele
DIABETOLOGIA, 2021, 64 (05) : 1079 - 1092
[46] Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial
Robin Assfalg
Jan Knoop
Kristi L. Hoffman
Markus Pfirrmann
Jose Maria Zapardiel-Gonzalo
Anna Hofelich
Anne Eugster
Marc Weigelt
Claudia Matzke
Julia Reinhardt
Yannick Fuchs
Melanie Bunk
Andreas Weiss
Markus Hippich
Kathrin Halfter
Stefanie M. Hauck
Jörg Hasford
Joseph F. Petrosino
Peter Achenbach
Ezio Bonifacio
Anette-Gabriele Ziegler
Diabetologia, 2021, 64 : 1079 - 1092
[47] Type 1 diabetes vaccine candidate enters phase 2 trial
不详
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (05) : 1079 - 1079
[48] Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
Marie-Léa Gauci
Philippe Boudou
Barouyr Baroudjian
Tiphaine Vidal-Trecan
Laetitia Da Meda
Isabelle Madelaine-Chambrin
Nicole Basset-Seguin
Martine Bagot
Cécile Pages
Samia Mourah
Matthieu Resche-Rigon
Sylvine Pinel
Marion Sassier
Franck Rouby
Pirayeh Eftekhari
Céleste Lebbé
Jean-François Gautier
Cancer Immunology, Immunotherapy, 2018, 67 : 1197 - 1208
[49] Qualitative study of barriers to clinical trial retention in adults with recently diagnosed type 1 diabetes
Henshall, Catherine
Narendran, Parth
Andrews, Robert C.
Daley, Amanda
Stokes, Keith A.
Kennedy, Amy
Greenfield, Sheila
BMJ OPEN, 2018, 8 (07):
[50] World Diabetes Day: Perspectives on immunotherapy of Type 1 Diabetes
Chatenoud, Lucienne
EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (11) : 2968 - 2970

← 1 2 3 4 5 →